Pillsbury: Sentynl Therapeutics Closes on Asset Acquisition of CUTX-101 Copper Histidinate Product Candidate From Cyprium Therapeutics
December 07, 2023
December 07, 2023
NEW YORK, Dec. 7 -- Pillsbury, a law firm, issued the following news release:
Pillsbury advised Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company wholly owned by Zydus Lifesciences, Ltd., in a recent closing with Cyprium Therapeutics, a Fortress Biotech, Inc. (Nasdaq: FBIO) subsidiary company.
According to a company press release, Cyprium completed the transfer to Sentynl of worldwide proprietary rights and U.S. FDA documents pertaining to CUTX-101, the . . .
Pillsbury advised Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company wholly owned by Zydus Lifesciences, Ltd., in a recent closing with Cyprium Therapeutics, a Fortress Biotech, Inc. (Nasdaq: FBIO) subsidiary company.
According to a company press release, Cyprium completed the transfer to Sentynl of worldwide proprietary rights and U.S. FDA documents pertaining to CUTX-101, the . . .